CordenPharma Chenôve increases lipid manufacturing capacity to support mRNA vaccine strategy CordenPharma, a full-service CDMO, has kicked off a major investment project to increase lipid manufacturing capacity at its Chenôve facility, near Dijon, France. This strategic decision was a result of the greatly increased demand to supply millions of…..
Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics Touchlight, a UK biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has concluded a development and manufacturing pipeline agreement with Versameb, a Swiss pre-clinical stage company focused on discovering and…..
MaaT Pharma and SkyePharma to establish the first microbiome-based therapeutics manufacturing facility in France MaaT Pharma and Skyepharma have entered a partnership agreement to build SkyeHub Bioproduction, a new manufacturing facility near Lyon. This new plant will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. SkyeHub Bioproduction…..
« L’innovation en bioproduction n’est pas un champ aride en France » Le Grand Défi « Biomédicaments : améliorer les rendements et maîtriser les coûts de production » a maintenant sélectionné 10 projets retenus dans le cadre de ses premiers appels à projets. Alors qu’une nouvelle vague de lauréats va être annoncée prochainement,…..
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a…..
GTP Bioways is acquiring IDBiotech and invests €12M in two GMP biopharmaceutical production units Acquisition of CRO IDBiotech GTP Bioways, a French CDMO (Contract Development and Manufacturing Organization) specializing in the production of biotherapies and nanotherapies, has acquired IDBiotech. Based in Issoire (France), this CRO specialises in the development…..
Second phase II study for zilebesiran, an RNAi therapeutic for the treatment of hypertension Alnylam Pharmaceuticals, a leading RNAi therapeutics company, has initiated KARDIA-2 (NCT05103332), a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen…..
First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™) for the treatment of myotonic dystrophy type 1 (DM1) Avidity Bioscience, a californian biotech company committed to delivering a new class of RNA therapeutics, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with its lead…..
A new European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases Members of the European Platform for Neurodegenerative Diseases (EPND) will embark on a venture to establish a collaborative platform for efficient sample and data sharing, leveraging and linking existing European research infrastructures to accelerate the…..
New large-scale DNA manufacturing facility in the UK Touchlight, a UK-based manufacturer of synthetic DNA, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of…..
- Page Précédente
- 1
- 2
- 3
- 4
- 5
- 6
...
- 21
- Page Suivante
